(Q24235411)

2

0 references

Irit Ben-Aharon

3

0 references

Elad Goldberg

4

0 references

Femi Pitan

5

0 references

Nigel Cunliffe

Cochrane Database of Systematic Reviews

6

0 references

publication date

12 May 2010

0 references

published in

0 references

cites work

Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

A short report on highlights of world-wide development of RIX4414: a Latin American experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

The future of rotavirus vaccines: a major setback leads to new opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

A short report on clinical evaluation of RIX4414: highlights of world-wide development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

A short report on highlights of world-wide development of RIX4414: an European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Pentavalent human-bovine reassortant rotavirus vaccine: a review of its efficacy and safety in preventing acute rotavirus gastroenteritis in healthy infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Evaluating the safety of a rotavirus vaccine: the REST of the story

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus vaccine (RotaTeq).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus live, oral, pentavalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Development of candidate rotavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus vaccines: targeting the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Selected regulatory and scientific topics for candidate rotavirus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Diarrhea- and Rotavirus-Associated Hospitalizations Among Children Less Than 5 Years of Age: United States, 1997 and 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

The impact of rotavirus gastroenteritis on the family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Options for the prevention of rotavirus disease other than vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus vaccines: entering a new stage of deployment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Global Illness and Deaths Caused by Rotavirus Disease in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Effect of rotavirus vaccination on death from childhood diarrhea in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus vaccine--a powerful tool to combat deaths from diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

More on RotaShield and intussusception: the role of age at the time of vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus vaccines against diarrhoeal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Rotavirus vaccine for preventing diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Will pediatricians adopt the new rotavirus vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

A short report on the highlights of world-wide development of RIX4414: a North American experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Efficacy of the Human Rotavirus Vaccine RIX4414 in Malnourished Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

Introduction to Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Strategies for the development of a rotavirus vaccine against infantile diarrhea with an update on clinical trials of rotavirus vaccines.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Introduction of human rotavirus vaccine in Latin America

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

A short report on highlights of worldwide development of RIX4414: a Singaporean experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Rotavirus serotype G9 is associated with more-severe disease in Latin America

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Rotavirus: the search for the next generation vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Preventing rotavirus gastroenteritis: do you have the facts?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Public health. Progress toward rotavirus vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. American Academy of Pediatrics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Rotavirus vaccine--AVANT immunotherapeutics/GlaxoSmithKline: 89-12, RIX4414

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021

Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521

7 January 2021